Key facts
- This page summarizes Kristen L. Alexander's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 Feb 2025, 16:22.
Kristen L. Alexander - 13 Feb 2025 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)
- Reporting relationship
- VP, Finance and Accounting
- Issuer ticker
- LXRX
- Reported as of
- 13 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Feb 2025, 16:22:50 UTC
- Prior SEC filing
- 29 Feb 2024
- Next SEC filing
- 03 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kristen L. Alexander
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kristen L. Alexander filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 18 Feb 2025.
Change
- Previous filing in this sequence was filed on 29 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LXRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +185,540
- Change %
- Price
- $0.000000
- Shares after
- 185,540
- Date
- 13 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 185,540
- Exercise price
- $0.6950
- Footnotes
- F1
LXRX
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +185,540
- Change %
- Price
- $0.000000
- Shares after
- 185,540
- Date
- 13 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 185,540
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F3
Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.